1
Manuel Baca, James A Wells: Anti-VEGF antibodies. Genentech, Genentech, April 26, 2005: US06884879 (146 worldwide citation)

Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.


2
Manuel Baca, James A Wells, Leonard G Presta, Henry B Lowman, Yvonne Man yee Chen: Anti-VEGF antibodies. Genentech, Steven X Cui, Genentech, June 13, 2006: US07060269 (61 worldwide citation)

Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.


3
Andrew C Chan, Robert L Shields, Lawren Wu: Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor. Genentech, Genentech, Craig G Svoboda, February 16, 2010: US07662926 (35 worldwide citation)

The present application describes antibodies that selectively bind human FcγRIIB, with little or no binding to other human FcγRs, e.g., human FcγRIIA. The invention also provides isolated bispecific antibodies comprising an antibody that selectively binds FcγRIIB, and a second antibody that specific ...


4
Manuel Baca, James A Wells, Leonard G Presta, Henry B Lowman, Yvonne Man yee Chen: Anti-VEGF antibodies. Genentech, Steven X Cui, Genentech, January 30, 2007: US07169901 (34 worldwide citation)

Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.


5
Charles W Eigenbrot, Jagath Reddy Junutula, Henry Lowman, Helga E Raab, Richard Vandlen: Cysteine engineered antibodies and conjugates. Genentech, Genentech, Alex Andrus, December 21, 2010: US07855275 (32 worldwide citation)

Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design ...


6
Kenneth J Hillan, Ralph H Schwall, Kelly H Tabor: Hepatocyte growth factor receptor agonists and uses thereof. Genentech, Genentech, August 8, 2000: US06099841 (27 worldwide citation)

Hepatocyte growth factor (HGF) receptor agonists are provided. The HGF receptor agonists include HGF receptor antibodies and fragments thereof. The HGF receptor agonists can be employed to substantially enhance HGF receptor activation. The HGF receptor agonists may be included in pharmaceutical comp ...


7
Gregory S Blank, Daljit S Narindray, Gerardo A Zapata: Protein recovery. Genentech, Lee K Genentech Tan, September 19, 2000: US06121428 (19 worldwide citation)

The invention herein provides a method for recovering a polypeptide comprising exposing a composition comprising a polypeptide to a reagent which binds to, or modifies, the polypeptide, wherein the reagent is immobilized on a solid phase; and then passing the composition through a filter bearing a c ...


8
Kyung Jin Kim: Antibodies to vascular endothelial cell growth factor. Genentech, Steven X Cui, Genentech, June 5, 2007: US07227004 (17 worldwide citation)

The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoc ...


9
Jagath Reddy Junutula, Henry Lowman: Cysteine engineered antibodies and conjugates. Genentech, Alex Andrus, Genentech, November 13, 2012: US08309300 (16 worldwide citation)

Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design ...


10
Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong: Apoptotic anti-IgE antibodies. Genentech, Genentech, Craig G Svoboda, December 6, 2011: US08071097 (11 worldwide citation)

The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.